BRPI0611009A2 - usos de um anticorpo monoclonal (mab), e, de um anticorpo anti-hgf de neutralização - Google Patents

usos de um anticorpo monoclonal (mab), e, de um anticorpo anti-hgf de neutralização Download PDF

Info

Publication number
BRPI0611009A2
BRPI0611009A2 BRPI0611009-6A BRPI0611009A BRPI0611009A2 BR PI0611009 A2 BRPI0611009 A2 BR PI0611009A2 BR PI0611009 A BRPI0611009 A BR PI0611009A BR PI0611009 A2 BRPI0611009 A2 BR PI0611009A2
Authority
BR
Brazil
Prior art keywords
mab
use according
hgf
growth factor
nrg
Prior art date
Application number
BRPI0611009-6A
Other languages
English (en)
Portuguese (pt)
Inventor
John Laterra
Bachchu Lal
Kyung Jin Kim
Original Assignee
Galaxy Biotech Llc
Kennedy Krieger Inst Inc
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galaxy Biotech Llc, Kennedy Krieger Inst Inc, Univ Johns Hopkins filed Critical Galaxy Biotech Llc
Publication of BRPI0611009A2 publication Critical patent/BRPI0611009A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0611009-6A 2005-06-02 2006-06-01 usos de um anticorpo monoclonal (mab), e, de um anticorpo anti-hgf de neutralização BRPI0611009A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US68711805P 2005-06-02 2005-06-02
US60/687,118 2005-06-02
US75109205P 2005-12-15 2005-12-15
US60/751,092 2005-12-15
PCT/US2006/021293 WO2006130773A2 (fr) 2005-06-02 2006-06-01 Methodes de traitement des tumeurs du cerveau a l'aide d'anticorps

Publications (1)

Publication Number Publication Date
BRPI0611009A2 true BRPI0611009A2 (pt) 2010-08-10

Family

ID=37482322

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0611009-6A BRPI0611009A2 (pt) 2005-06-02 2006-06-01 usos de um anticorpo monoclonal (mab), e, de um anticorpo anti-hgf de neutralização

Country Status (14)

Country Link
US (2) US20070036797A1 (fr)
EP (1) EP1885400A4 (fr)
JP (2) JP2008545753A (fr)
KR (1) KR20080026562A (fr)
AU (1) AU2006252419B2 (fr)
BR (1) BRPI0611009A2 (fr)
CA (1) CA2607699A1 (fr)
CR (1) CR9512A (fr)
IL (1) IL187318A0 (fr)
MA (1) MA29570B1 (fr)
MX (1) MX2007015056A (fr)
NO (1) NO20080012L (fr)
RU (1) RU2007146986A (fr)
WO (1) WO2006130773A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
EP1934261B1 (fr) * 2005-09-26 2014-10-29 Medarex, L.L.C. Anticorps monoclonaux humains diriges contre cd70
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
MX2008015138A (es) 2006-06-02 2009-01-28 Aveo Pharmaceuticals Inc Proteinas de union al factor de crecimiento de hepatocitos (fch).
US7649083B2 (en) 2006-06-02 2010-01-19 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding antibody
HRP20160082T1 (hr) 2006-09-29 2016-02-26 Oncomed Pharmaceuticals, Inc. Sastavi i postupci za dijagnosticiranje i lijeäśenje raka
US20100150950A1 (en) * 2006-12-14 2010-06-17 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
BRPI0816142A2 (pt) * 2007-08-24 2015-02-18 Novartis Ag Modulador de nrg1 para tratamento de distúrbios respiratórios.
TW200948380A (en) * 2008-04-11 2009-12-01 Galaxy Biotech Llc Combination of HGF inhibitor and PTEN agonist to treat cancer
US20110217294A1 (en) * 2008-04-11 2011-09-08 Daniel Fults Combination of hgf inhibitor and hedgehog inhibitor to treat cancer
KR101590495B1 (ko) * 2008-05-29 2016-02-01 갤럭시 바이오테크, 엘엘씨 염기성 섬유모세포 성장 인자에 대한 모노클로날 항체
WO2010119991A2 (fr) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Nouveau procédé de traitement anticancéreux
EP3485908B1 (fr) 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Combinaison thérapeutique et utilisation d'anticorps antagonistes de dll4 et d'agents anti-hypertenseurs
ES2519348T3 (es) * 2010-02-18 2014-11-06 Genentech, Inc. Antagonistas de neurregulina y uso de los mismos en el tratamiento del cáncer
RU2439160C1 (ru) * 2010-06-25 2012-01-10 Государственное общеобразовательное учреждение высшего профессионального образования "Российский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО РГМУ Росздрава) Способ получения моноклональных антител к аблюминальному мембранному антигену церебральных эндотелиоцитов
EP2588107A1 (fr) * 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited Combinaison d'un inhibiteur de cmet et d'un anticorps dirigé contre hgf et/ou cmet
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9783601B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
TWI583699B (zh) 2011-09-23 2017-05-21 安可美德藥物股份有限公司 Vegf/dll4結合劑類及彼等之用途
CA2889638A1 (fr) 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methodes et surveillance d'un traitement par un antagoniste de dll4
EP3212233B1 (fr) 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Thérapie combinée pour le traitement d'une maladie
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2564486B2 (ja) * 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US6498144B1 (en) * 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5707624A (en) * 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
ATE465257T1 (de) * 1996-07-03 2010-05-15 Genentech Inc Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen
WO2004019991A2 (fr) * 2002-08-30 2004-03-11 F. Hoffmann-La Roche Ag Antagoniste nk4 du facteur de croissance de l'hepatocyte/du facteur de dispersion pour le traitement de gliome
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US7220410B2 (en) * 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
EA015363B1 (ru) * 2003-07-18 2011-06-30 Эмджен Инк. Агенты, специфически связывающие фактор роста гепатоцитов, и их применение
EP2210607B1 (fr) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(méthyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phényl]-N'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide pour le traitement du cancer
CA2572331A1 (fr) * 2004-07-02 2006-02-09 Exelixis, Inc. Modulateurs de c-met et leur methode d'utilisation
WO2007056523A2 (fr) * 2005-11-08 2007-05-18 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Procedes de diagnostic et de surveillance de la progression d'un cancer
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
US20110217294A1 (en) * 2008-04-11 2011-09-08 Daniel Fults Combination of hgf inhibitor and hedgehog inhibitor to treat cancer
PE20091827A1 (es) * 2008-04-11 2009-11-20 Galaxy Biotech Llc Combinacion del inhibidor hgf y el inhibidor egf para el tratamiento del cancer

Also Published As

Publication number Publication date
JP2013136580A (ja) 2013-07-11
EP1885400A2 (fr) 2008-02-13
NO20080012L (no) 2008-02-20
MA29570B1 (fr) 2008-06-02
EP1885400A4 (fr) 2011-01-26
WO2006130773A2 (fr) 2006-12-07
WO2006130773A3 (fr) 2009-04-16
JP2008545753A (ja) 2008-12-18
RU2007146986A (ru) 2009-06-27
CA2607699A1 (fr) 2006-12-07
CR9512A (es) 2008-04-16
MX2007015056A (es) 2008-03-11
KR20080026562A (ko) 2008-03-25
US20100221250A1 (en) 2010-09-02
US20070036797A1 (en) 2007-02-15
AU2006252419A1 (en) 2006-12-07
AU2006252419B2 (en) 2012-02-02
IL187318A0 (en) 2008-04-13

Similar Documents

Publication Publication Date Title
US20100221250A1 (en) Methods of treating brain tumors with antibodies
AU2004319276B2 (en) Monoclonal antibodies to hepatocyte growth factor
US7220410B2 (en) Monoclonal antibodies to hepatocyte growth factor
AU2007233242B2 (en) Humanized monoclonal antibodies to hepatocyte growth factor
US20090258014A1 (en) Combination of hgf inhibitor and egf inhibitor to treat cancer
US20110217294A1 (en) Combination of hgf inhibitor and hedgehog inhibitor to treat cancer
KR101590495B1 (ko) 염기성 섬유모세포 성장 인자에 대한 모노클로날 항체
US20120052064A1 (en) Anti-hgf antibody combinational cancer therapies
CN101511386A (zh) 用抗体治疗脑肿瘤的方法

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2256 DE 01/04/2014.